Advancis Pharmaceutical said that its lead product, a once-a-day version of the widely used antibiotic amoxicillin, has failed testing for a second time. In its study of its drug in children with strep throat, it was only 65.3 percent successful, far less than the 85 percent needed to qualify as a primary treatment. Standard penicillin worked better. Advancis has about $40 million in cash and could afford more testing, but company executives said they will have to take a critical look at whether it is worth the risk.
- read this article from The Washington Post for more